基本信息
浏览量:7
职业迁徙
个人简介
He brings over twenty-five years of Pharma experience leading teams that have selected more than 150 candidate drugs for the treatment of human disease and advanced about 20 NME candidate drugs towards late-stage development drugs through registration and successful drug approvals . Under Mikael’s leadership, Pfizer has, as of Q3 2016, achieved about 20 approvals of which more than half are New Medical Entities (NME), ranging from therapies for rheumatoid arthritis, stroke prevention and cancer to a pneumococcal vaccine.
研究兴趣
论文共 13 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Charles H Jones,Mikael Dolsten
npj agingno. 1 (2024): 25-25
Charles Jones,Mikael Dolsten
NPJ AGINGno. 1 (2024): 22-22
Charles H. Jones, John R. Androsavich, Nina So, Matthew P. Jenkins, Derek MacCormack, Andrew Prigodich,Verna Welch,Jane M. True,Mikael Dolsten
npj Genomic Medicineno. 1 (2024): 1-14
Charles H. Jones, John R. Androsavich, Nina So, Matthew P. Jenkins, Derek Maccormack, Andrew Prigodich,Verna Welch,Jane M. True,Mikael Dolsten
NPJ GENOMIC MEDICINEno. 1 (2024)
Nicholas Warne, Margaret Ruesch, Pamela Siwik, Paul Mensah, John Ludwig, Michael Hripcsak, Ranga Godavarti, Andrew Prigodich,Mikael Dolsten
Kathy Fernando,Sandeep Menon,Kathrin Jansen, Prakash Naik,Gianluca Nucci, John Roberts,Shuang Sarah Wu,Mikael Dolsten
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn